Redeye states that CoinShares’ Q4 2024 report was strong, with beats across all segments.
Extended Fenja loan (SEK 55m) with new SEK 20m option New shareholder loan (SEK 22.
Redeye comments on Truecaller’s Q4 2024 report, which exceeded expectations on all levels.
Rec. PTP adj. -13% vs ABGSCe Financial net impacted by one-offs Cons to lower rec.
Redeye updates its estimates and fair value range following Arise’s Q4 2024 report, which marked the...
Net sales were in line with our expectation, but clean EBITA was a bit weaker than we had forecast f...
Q4 below, Q1 likely better Pulp prices rising amid price hikes Fair value range: SEK 9-16/sh Q4 bel...
Another quarter of y-o-y margin improvement Margin-driven EBITA upgrades of 6-4% for '25e-'26e Share...
Obducat (”Obducat” eller ”Bolaget”) publicerade den 14 februari 2025 Bolagets delårsrapport för det ...
Alisa Bank’s H2 was in line with our expectations on profitability while growth was more constrained...
Redeye shares its preview of BONESUPPORT’s Q4 2024 results, due February 25.
Minor estimate revisions Delivery of IC2000 within one quarter of order 3.
ESL Shipping segment reported clean EBITA of EUR 4.
Redeye returns with a more in-depth take on Sedana Medical’s Q4 report.
Redeye updates its view on Genovis following the company's year-end report.
